What is the current Price Target for the MEI Pharma, Inc. stock?

The average MEI Pharma, Inc. target price is $6.12. This is 118.57% higher than the current stock price. The highest price target is 125.00%, the lowest is 116.43%. 3 Analysts have issued a price target MEI Pharma, Inc. 2026 .

How high will the MEI Pharma, Inc. stock rise?

No reliable answer can be given as to how high the MEI Pharma, Inc. stock will rise. The performance of stocks, including the MEI Pharma, Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the MEI Pharma, Inc. stock today?

The performance of MEI Pharma, Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the MEI Pharma, Inc. stock fall?

The decline in MEI Pharma, Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

MEI Pharma, Inc. Forecast, price target & analysts

$2.80

4.09% yesterday

Nasdaq, Jun 27, 10:00 pm CET

ISIN

US55279B2025

Symbol

MEIP

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

MEI Pharma, Inc. Target price 2025 - Analyst rating & recommendation

MEI Pharma, Inc. Classifications & Recommendation:

Hold

50%

Sell

50%

MEI Pharma, Inc. Price Target

Target Price	$6.12
Price	$2.80
Potential	118.57% register free of charge
Number of Estimates	3

	3 Analysts have issued a price target MEI Pharma, Inc. 2026 . The average MEI Pharma, Inc. target price is $6.12. This is 118.57% register free of charge higher than the current stock price. The highest price target is $6.30 125.00% register free of charge , the lowest is $6.06 116.43% register free of charge .
	A rating was issued by 6 analysts: 0 Analysts recommend MEI Pharma, Inc. to buy, 3 to hold and 3 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the MEI Pharma, Inc. stock has an average upside potential 2026 of 118.57% register free of charge . Most analysts recommend the MEI Pharma, Inc. stock at Sell or hold.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 & 2027

Create a premium account to unlock analyst estimates. Learn more

Annually

	Jun '24	2025 Estimates
Earnings Per Share $	2.67	-6.41
	155.86%	340.07%
P/E		negative

3 Analysts have issued a MEI Pharma, Inc. forecast for earnings per share. The average MEI Pharma, Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$2.67	155.86%
2025	$-6.41 340.07% Unlock
2026	$-3.78 41.03% Unlock
2027	$-1.59 57.94% Unlock

Current	-0.59	180.80%
2025	-0.44 25.36% Unlock
2026	-0.74 68.18% Unlock
2027	-1.76 137.84% Unlock

MEI Pharma, Inc....

Discover more stocks with a high price target

Berkshire Hathaway 154,261.00%

Alibaba Group Holding Ltd 1,077.45%

BioNTech SE - ADR 31.42%

Tencent Holdings Ltd. 26.26%

Adyen 24.86%

Deutsche Telekom 24.51%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now